FIELD DEFINITIONS

(* = Required field)

(† = Public by default, can be hidden)

(‡ = Will remain hidden until project end date)

PART I: YOUR STUDY: INFORMATION YOU NEED TO PROVIDE AT THE TIME WHEN YOU REGISTER

▸ Trial Information

TRIAL INFORMATION

1. Trial Title* - Typically the title on the IRB original application
2. Registration Number - *Assigned by the system on initial posting*
3. Registration Date - *Date of initial posting, assigned by system*
4. Last Updated - *Date entry was last modified, assigned by system*
5. Country*‡ - Location of trial
6. Region - Regional location of trial (ie. Africa, South Asia, etc.)
7. Primary Investigator* - *By default, it's the person creating the draft trial (assigned by system).* This can be changed once another user has been added as a collaborator.
8. Other Primary Investigator(s) - Other PIs or Co-PIs on the trial
9. Status* - Has the study been:
   - Completed?
   - Ongoing?
   - In development?
   - Withdrawn / Abandoned?
10. Keywords* - Choose one or more of the 10 listed themes:
    - Agriculture
    - Education
    - Electoral
    - Environment & Energy
    - Finance & Microfinance
    - Governance
    - Health
    - Labor
    - Post-conflict
    - Welfare
11. Additional Keywords - Enter some English words which describe your trial more specifically than the above theme (e.g. job placement, voter education, conservation, etc.)
12. JEL Code(s) - Journal of Economic Literature (JEL) classification system code. For example, O16 for "Financial Markets; Saving and Capital Investment; Corporate Finance and Governance." A list of possible codes can be found at https://www.aeaweb.org/jel/jel_class_system.php. [Opens in new window]
13. Secondary Identifying Numbers - Numbers given to the trial by other funders, sponsors or registries (ClinicalTrials.gov, ISRCT, etc.).
14. Abstract* - Summarize the information above in plain English, to clarify the objectives of the study: what are the main outcome(s) you are studying, the intervention(s), the level of randomization and the sample size.
15. External Links - Links to any other related material

DATES

16. Trial Start Date* - Date at which you start the baseline or preparatory work (e.g. conduct a census). The very latest should be the date when randomized implementation of the intervention begins. Format: YYYY/MM/DD
17. Intervention Start Date* - The date you start the administration of the intervention (after random assignment). This should match the trial start date documented on your IRB protocol. Format: YYYY/MM/DD
18. Intervention End Date* - Planned end date of administering the intervention. Format: YYYY/MM/DD
19. Trial End Date* - Date by which you expect to complete a report after analysis of data, or the date on IRB closure notification. Format: YYYY/MM/DD

▸ Sponsors & Partners

SPONSORS & PARTNERS (OPTIONAL)

20. Trial Sponsor(s) ‡ - Sources of monetary or material support
21. Trial Partner(s)† ‡- Organization(s) or entity(s) involved in implementing the intervention (ie. treatment(s))

▸ Experimental Details

EXPERIMENTAL DETAILS

22. Intervention(s)† - What are the different treatment groups conditions in your experiment? The "public" option makes this field viewable to all, once published. The "hidden" option makes this field not viewable to the public until your trial is completed. Trial completion depends on what you put in the Trial End Date field.
23. Outcomes (end points)* - What are your key outcome variables (indicators) of interest in this experiment, upon which final impact will be measured?
24. Outcomes (explanation) - Provide here a description of how the outcome will be constructed from the main variables/indicators. Be as specific as possible with the measure used.
25. Experimental Design*† - What are the different treatment groups conditions in your experiment? The "public" option makes this field viewable to all, once published. The "hidden" option makes this field not viewable to the public until your trial is completed (ie. what you put in the Trial End Date field is the completion date).
26. Randomization Method*- ie. Through public lottery, randomization done in office by a computer, coin flip, etc.
27. Randomization Unit* - Unit (clusters) of randomization (e.g., individual, firm, school, experimental sessions). If you have more than one level of randomization (e.g. group level randomization for some treatment, and individual randomization for some treatments) explain it here.
28. Was the treatment clustered* - [Yes/No] Are groups of subjects (as opposed to individual subjects) randomized?
29. Sample Size: Planned Number of Clusters (unit of randomization)* - How many groupings, and by what unit? e.g. 200 schools
30. Sample size: Planned Total number of observations* - The total maximum recruitment of participants/individuals for the trial, across all treatment arms (eg. 10,000 pupils)
31. Sample size (or number of clusters) by treatment arms* - e.g. 50 schools control, 50 schools teacher training, 50 schools scholarship, 50 schools both treatment
32. Power calculation - Accounting for sample design and clustering, what is the minimum detectable effect size for main outcomes. Specify the unit, standard deviation, and percentage.

▸ IRB

INSTITUTIONAL REVIEW BOARD (IRB) INFORMATION

33. Did you obtain IRB approval* - [Yes/No]
    - If you have no IRB approval yet, please enter details of when and with whom you plan to submit.
    - Note: If the project has gone through multiple IRBs at different institutions, please list them all separately.
34. Full Name IRB Board* - Name of institution or organization listed on award letter
35. Date of IRB Approval* - Found on the approval letter. Format: YYYY/MM/DD
36. IRB Approval Number* - Numerical or alphanumerical combination found on the approval letter. Varies by institution.

▸ Supporting Documents and Materials

DOCS & MATERIALS (OPTIONAL)

In this section, you can upload any document that you think may be useful to others to interpret your work or as they design their own work, including survey instruments, proposal(s), and protocols submitted to IRB, or others. These documents will be kept private until you authorize their release.

▸ Analysis Plan

ANALYSIS PLAN (OPTIONAL)

Here, if you wish, upload an analysis plan(s) with as much details as you would like. You can do this at any point in the process or not at all. If a new copy is uploaded, the system will track all the versions and the date at which they were submitted. Note: the information is private by default until the PI authorizes the release (to the public or to a specific person).

PART II: INFORMATION YOU NEED TO PROVIDE WHEN STUDY IS COMPLETE, WITHDRAWN/ ABANDONED OR AT KEY STAGE OF THE STUDY

▸ Post Trial Information

STUDY STATUS

1. Was this trial withdrawn? [Yes/No]
   - If so, when was the study withdrawn? Format: YYYY/MM/DD
   - If so, what was the withdrawal cause?
2. Is the intervention completed? [Yes/No]
   - If so, on what date was it completed? – Final/end date of administering the intervention. Format: YYYY/ MM/DD
3. Is data collection complete? [Yes/No]
   - If so, on what date was it completed? Format: YYYY/ MM/DD
   - If so, final sample size: Number of Clusters (Unit of Randomization) - Units actually treated, e.g. 198 Schools.
   - If so, was attrition correlated with treatment status? [Yes/No] - Do the characteristics of those who drop out of the study differ in different treatment groups? This can be shown by summarizing baseline characteristics of those who drop out of the study, separately for each of the treatment groups, and testing whether the difference along any specific characteristic are statistically significant, and whether all differences are jointly statistically significant.
   - If so, final sample size: Total Number of Observations - Units actually observed, e.g. 9,500 pupils.
   - If so, final sample size (or number of clusters) by treatment arms - e.g. 50 schools control, 50 schools teach training, 50 schools scholarship, 50 schools both treatment.
4. Is the data available for public use? [Yes/No]
   - If so, what is the URL?
5. Is the data available for restricted use? [Yes/No]
   - If so, what is the contact email address?
6. Are program files posted for public use? e.g. Stata .do files [Yes/No]
   - If so, what is the URL?
7. Is there a preliminary report on results available to share? [Yes/No]
   - If so, add any preliminary reports which you are comfortable sharing publicly.
8. If you wish, add any working papers or publications.

CONTACT:

Keesler Welch, Trial Registry Administrator | J-PAL Global
keesler@mit.edu